Free cookie consent management tool by TermsFeed Policy Generator

Ensayos Clínicos

Phase III Randomized double-blind, placebo-controlled study investigating the efficacy of the addition of crenolaninb to salvage chemotherapy alone in subjects less than 75 years of age with Relapsed/refractory FLT3 Mutated Acute Leukemia

Ficha Técnica

Investigador Principal

JOSEFINA SERRANO LÓPEZ

Promotor

AROG PHARMACEUTICALS, INC.

ESTADO

ACTIVO

DEPARTAMENTO

Hematología y Hemoterapia

Código EudraCT: 2019-001600-29

Número protocolo: ARO-013

Fecha Inicio: 2019-06-24

Fecha Fin: 2024-10-31